Hepatitis C Treatment in People With HIV : Potential to Eliminate Disease and Disparity
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
Access to direct acting antivirals (DAAs) may be associated with reductions in hepatitis C virus (HCV) viremia prevalence among people with human immunodeficiency virus (PWH). Among 3755 PWH, estimated HCV viremia prevalence decreased by 94.0% from 36% (95% confidence interval [CI], 27%-46%) in 2009 (pre-DAA era) to 2% (95% CI, 0%-4%) in 2021 (DAA era). Male sex, black race, and older age were associated with HCV viremia in 2009 but not in 2021. Injection drug use remained associated with HCV viremia in 2009 and 2021. Targeted interventions are needed to meet the HCV care needs of PWH who use drugs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:229 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 229(2024), 3 vom: 14. März, Seite 775-779 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Falade-Nwulia, Oluwaseun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 15.03.2024 Date Revised 16.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiad433 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362868921 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362868921 | ||
| 003 | DE-627 | ||
| 005 | 20240316232549.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiad433 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1332.xml |
| 035 | |a (DE-627)NLM362868921 | ||
| 035 | |a (NLM)37793170 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Falade-Nwulia, Oluwaseun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatitis C Treatment in People With HIV |b Potential to Eliminate Disease and Disparity |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2024 | ||
| 500 | |a Date Revised 16.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a Access to direct acting antivirals (DAAs) may be associated with reductions in hepatitis C virus (HCV) viremia prevalence among people with human immunodeficiency virus (PWH). Among 3755 PWH, estimated HCV viremia prevalence decreased by 94.0% from 36% (95% confidence interval [CI], 27%-46%) in 2009 (pre-DAA era) to 2% (95% CI, 0%-4%) in 2021 (DAA era). Male sex, black race, and older age were associated with HCV viremia in 2009 but not in 2021. Injection drug use remained associated with HCV viremia in 2009 and 2021. Targeted interventions are needed to meet the HCV care needs of PWH who use drugs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a elimination | |
| 650 | 4 | |a health equity | |
| 650 | 4 | |a hepatitis C | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Lesko, Catherine R |e verfasserin |4 aut | |
| 700 | 1 | |a Fojo, Anthony T |e verfasserin |4 aut | |
| 700 | 1 | |a Keruly, Jeanne C |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Richard D |e verfasserin |4 aut | |
| 700 | 1 | |a Sutcliffe, Catherine G |e verfasserin |4 aut | |
| 700 | 1 | |a Mehta, Shruti H |e verfasserin |4 aut | |
| 700 | 1 | |a Chander, Geetanjali |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, David L |e verfasserin |4 aut | |
| 700 | 1 | |a Sulkowski, Mark |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 229(2024), 3 vom: 14. März, Seite 775-779 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:229 |g year:2024 |g number:3 |g day:14 |g month:03 |g pages:775-779 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiad433 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 229 |j 2024 |e 3 |b 14 |c 03 |h 775-779 | ||